These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 3499465

  • 1. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Nov 01; 139(9):3118-25. PubMed ID: 3499465
    [Abstract] [Full Text] [Related]

  • 2. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Jul 01; 139(1):221-7. PubMed ID: 3495599
    [Abstract] [Full Text] [Related]

  • 3. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY.
    J Immunol; 1989 Jun 15; 142(12):4441-9. PubMed ID: 2786033
    [Abstract] [Full Text] [Related]

  • 4. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.
    Bogdan C, Schröppel K, Lohoff M, Röllinghoff M, Solbach W.
    Eur J Immunol; 1990 Dec 15; 20(12):2533-40. PubMed ID: 1980108
    [Abstract] [Full Text] [Related]

  • 5. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.
    Scott P, Caspar P, Sher A.
    J Immunol; 1990 Feb 01; 144(3):1075-9. PubMed ID: 2295814
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY, Singleton A, Cillari E, Howard JG.
    J Immunol; 1985 Sep 01; 135(3):2102-7. PubMed ID: 3160786
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic immunization against experimental leishmaniasis. VI. Comparison of protective and disease-promoting T cells.
    Liew FY, Hodson K, Lelchuk R.
    J Immunol; 1987 Nov 01; 139(9):3112-7. PubMed ID: 3312413
    [Abstract] [Full Text] [Related]

  • 8. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.
    Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY.
    J Immunol; 1990 Oct 01; 145(7):2281-5. PubMed ID: 2144549
    [Abstract] [Full Text] [Related]

  • 9. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY, Howard JG, Hale C.
    J Immunol; 1984 Jan 22; 132(1):456-61. PubMed ID: 6228580
    [Abstract] [Full Text] [Related]

  • 11. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.
    Doherty TM, Coffman RL.
    J Immunol; 1993 Jun 15; 150(12):5476-83. PubMed ID: 8515072
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 13. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 14. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 29; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 15. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors.
    Nylén S, Maasho K, McMahon-Pratt D, Akuffo H.
    Scand J Immunol; 2004 Mar 29; 59(3):294-304. PubMed ID: 15030581
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 29; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 17. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O.
    Vaccine; 2006 Mar 10; 24(11):1800-10. PubMed ID: 16310900
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
    Shimizu Y, Takagi H, Nakayama T, Yamakami K, Tadakuma T, Yokoyama N, Kojima N.
    Parasite Immunol; 2007 May 10; 29(5):229-39. PubMed ID: 17430546
    [Abstract] [Full Text] [Related]

  • 19. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P, Sukumaran B, Saxena S, Madhubala R.
    Vaccine; 2004 Aug 13; 22(23-24):3053-60. PubMed ID: 15297055
    [Abstract] [Full Text] [Related]

  • 20. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA, Ogunremi O, Menon JN.
    Behring Inst Mitt; 1997 Feb 13; (98):153-9. PubMed ID: 9382736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.